- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Beovu® | brolucizumab-dbll | ESBA-1008 | ESBA1008 | RTH258
brolucizumab is an approved drug (FDA (2019), EMA (2020))
Compound class: Antibody
Comment: Brolucizumab is a single-chain variable fragment (scFv) anti-VEGF antibody targeting vascular endothelial growth factor A (VEGFA). This immunobinder was derived from a humanised anti-VEGFA rabbit monoclonal .
Peptide sequence and secondary structural information are available from brolucizumab's IMGT/mAb-DB record.
Peptide sequence alignment analysis of patented peptide sequences using the heavy chain variable region of brolucizumab identifies a 100% match with SEQ ID NO: 164 in patent US8349322 B2 .
Following regulatory approval brolucizumab took its place as a wet age-related macular degeneraton therapy alongside aflibercept (Eylea®) and ranibizumab (Lucentis®), which were previously the main drugs used for this indication. However, with patent protection for both of these older dugs due to expire in the next 2-5 years , brolucizumab will likely face competition from aflibercept and ranibizumab biosimilars.
|Approved drug?||Yes (FDA (2019), EMA (2020))|
|International Nonproprietary Names|
|Beovu® | brolucizumab-dbll | ESBA-1008 | ESBA1008 | RTH258|
|GtoPdb PubChem SID||252827371|
|Search PubMed clinical trials||brolucizumab|
|Search PubMed titles||brolucizumab|
|Search PubMed titles/abstracts||brolucizumab|